Generics - Oncology, Pricing

Filter

Current filters:

OncologyPricing

Popular Filters

Hospira refutes high pricing of paclitaxel during drug shortage

Hospira refutes high pricing of paclitaxel during drug shortage

08-06-2014

The Canadian subsidiary of USA-based injectable generic drugs specialist Hospira has refuted press reports…

CanadaGenericsHospiraMarkets & MarketingOncologyPaclitaxelPricing

Cancer treatments "unaffordable" and will drive rapid transition to generics and market decline, says GlobalData

10-05-2013

The rising prices of new cancer drugs are resulting in an increasing cost burden for patients and health…

BiotechnologyGenericsGlobalMarkets & MarketingOncologyPharmaceuticalPricing

Survey reveals 98.9% of US physicians experienced cancer drug shortages in last 12 months

15-11-2012

The Community Oncology Alliance (COA), a US non-profit organization, announced the results of a drug…

GenericsHealthcareNorth AmericaOncologyPharmaceuticalPricing

India's Cipla cuts prices of three cancer drugs

12-11-2012

Following what Indian drugmaker Cipla (BSE: 500087) said was an "overwhelming response" on the price…

Asia-PacificcapecitabineCipladocetaxelerlotinibGenericsOncologyPatentsPfizerPharmaceuticalPricingSunitinib MalateSutent

Cipla slashes price of generic cancer drug Nexavar in India by 76%; other cuts too

04-05-2012

Indian drugmaker Cipla (BSE: 500087) has slashed the prices of certain life-saving cancer drugs used…

Asia-PacificAstraZenecaBayerCiplaGenericsIressaMerck & CoNexavarOncologyPharmaceuticalPricingTemodar

Cancer drugs shortages persist in Poland

26-04-2012

In Poland, the recent procurement problems of cancer drugs is far from solved, writes Sebastian Gensior…

EuropeGenericsHealthcareNovartisOncologyPharmaceuticalPricingSandoz

Back to top